

Age and Health Care Expenditure - Cross-Country Evidence

Maciej Lis¹²

¹Institute for Structural Research (IBS),
maciej.lis@ibs.org.pl

²Warsaw School of Economics



ibs
INSTYTUT BADAŃ STRUKTURALNYCH

Research questions

- 1 *Does age structure of the population influence the aggregate health care expenditure?*
- 2 *Does time-to-death distribution of the population influence the aggregate health care expenditure?*
- 3 *How robust are these relationships?*



Outline

Motivation

Micro evidence

Data

Methods

Results



Why is the relationship between age and health care expenditure important?

Pressure of health care expenditure on public finance due to ageing:

- extending life-expectancy
- compression of mortality
- rising share of elderly in the population



Why is the relationship between age and health care expenditure important?

Pressure of health care expenditure on public finance due to ageing:

- extending life-expectancy
- compression of mortality
- rising share of elderly in the population



Why is the relationship between age and health care expenditure important?

Pressure of health care expenditure on public finance due to ageing:

- extending life-expectancy
- compression of mortality
- rising share of elderly in the population



Conclusions from literature

- huge effects of ageing on HCE with generational accounts methodology
- consensus on the moderate influence of ageing on the health care expenditure with “red herring” and time-to-death
- income, technological progress and institutional settings are crucial, but age remains significant for the rise of health care expenditure
- hardly any evidence from macro data and/or cross country comparison, even though the age-structure variables (like 65+) often included in macro models



Conclusions from literature

- huge effects of ageing on HCE with generational accounts methodology
- consensus on the moderate influence of ageing on the health care expenditure with “red herring” and time-to-death
- income, technological progress and institutional settings are crucial, but age remains significant for the rise of health care expenditure
- hardly any evidence from macro data and/or cross country comparison, even though the age-structure variables (like 65+) often included in macro models



Conclusions from literature

- huge effects of ageing on HCE with generational accounts methodology
- consensus on the moderate influence of ageing on the health care expenditure with “red herring” and time-to-death
- **income, technological progress and institutional settings are crucial, but age remains significant for the rise of health care expenditure**
- hardly any evidence from macro data and/or cross country comparison, even though the age-structure variables (like 65+) often included in macro models




Conclusions from literature


- huge effects of ageing on HCE with generational accounts methodology
- consensus on the moderate influence of ageing on the health care expenditure with “red herring” and time-to-death
- income, technological progress and institutional settings are crucial, but age remains significant for the rise of health care expenditure
- hardly any evidence from macro data and/or cross country comparison, even though the age-structure variables (like 65+) often included in macro models



Health care expenditure rises with age



But not for decedents



The macro approach - key points

- what are the effects of including measures of age structure of population and time-to-death simultaneously?
- calculate the time-to-death for every country and every year with the use of mortality rates
- use panel data estimators
- estimate models for all reasonable variations of time-to-death, time-to-death age threshold and age structure



The macro approach - key points

- what are the effects of including measures of age structure of population and time-to-death simultaneously?
- calculate the time-to-death for every country and every year with the use of mortality rates
- use panel data estimators
- estimate models for all reasonable variations of time-to-death, time-to-death age threshold and age structure



The macro approach - key points

- what are the effects of including measures of age structure of population and time-to-death simultaneously?
- calculate the time-to-death for every country and every year with the use of mortality rates
- use panel data estimators
- estimate models for all reasonable variations of time-to-death, time-to-death age threshold and age structure



The macro approach - key points

- what are the effects of including measures of age structure of population and time-to-death simultaneously?
- calculate the time-to-death for every country and every year with the use of mortality rates
- use panel data estimators
- estimate models for all reasonable variations of time-to-death, time-to-death age threshold and age structure



Data

- Human Mortality Database
- OECD and WHO data on health and macro variables
- final sample of 30 OECD countries and mean of 31 years per country (max 49, min 10)



Data

- Human Mortality Database
- **OECD and WHO data on health and macro variables**
- final sample of 30 OECD countries and mean of 31 years per country (max 49, min 10)



Data

- Human Mortality Database
- OECD and WHO data on health and macro variables
- final sample of 30 OECD countries and mean of 31 years per country (max 49, min 10)



Time-to-death calculation

The share of population $S_{a,i}$ at age $a \in \{0, 1, \dots, 110\}$ that will die in $i \in \{0, 1, \dots, 15\}$ years has been calculated through a transformation from unconditional to conditional death probability:

$$S_{a,i} = d_{a+i} \prod_{j=0}^{i-1} (1 - d_{a+j}) \quad (1)$$

where d_a is death rate at age a .

Generic model

$$h_{k,l} = \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (2)$$

or

$$h_{k,l} = \varphi h_{k,l-1} + \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (3)$$

where:

$h_{k,l}$ - the per capita health care expenditure in logarithm, at country k in year l

$S_{k,l}^{i,a}$ - share of population at country k in year l that will die in i years and is younger than a

$A_{k,l}^g$ - share of population younger than g at country k in year l

$X_{k,l}$ - GDP per capita (logarithm) at country k in year l

Generic model

$$h_{k,l} = \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (2)$$

or

$$h_{k,l} = \varphi h_{k,l-1} + \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (3)$$

where:

$h_{k,l}$ - the per capita health care expenditure in logarithm, at country k in year l

$S_{k,l}^{i,a}$ - share of population at country k in year l that will die in i years and is younger than a

$A_{k,l}^g$ - share of population younger than g at country k in year l

$X_{k,l}$ - GDP per capita (logarithm) at country k in year l

Generic model

$$h_{k,l} = \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (2)$$

or

$$h_{k,l} = \varphi h_{k,l-1} + \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (3)$$

where:

$h_{k,l}$ - the per capita health care expenditure in logarithm, at country k in year l

$S_{k,l}^{i,a}$ - share of population at country k in year l that will die in i years and is younger than a

$A_{k,l}^g$ - share of population younger than g at country k in year l

$X_{k,l}$ - GDP per capita (logarithm) at country k in year l

Generic model

$$h_{k,l} = \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (2)$$

or

$$h_{k,l} = \varphi h_{k,l-1} + \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (3)$$

where:

$h_{k,l}$ - the per capita health care expenditure in logarithm, at country k in year l

$S_{k,l}^{i,a}$ - share of population at country k in year l that will die in i years and is younger than a

$A_{k,l}^g$ - share of population younger than g at country k in year l

$X_{k,l}$ - GDP per capita (logarithm) at country k in year l

Generic model

$$h_{k,l} = \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (2)$$

or

$$h_{k,l} = \varphi h_{k,l-1} + \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (3)$$

where:

$h_{k,l}$ - the per capita health care expenditure in logarithm, at country k in year l

$S_{k,l}^{i,a}$ - share of population at country k in year l that will die in i years and is younger than a

$A_{k,l}^g$ - share of population younger than g at country k in year l

$X_{k,l}$ - GDP per capita (logarithm) at country k in year l

Generic model

$$h_{k,l} = \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (2)$$

or

$$h_{k,l} = \varphi h_{k,l-1} + \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (3)$$

where:

$h_{k,l}$ - the per capita health care expenditure in logarithm, at country k in year l

$S_{k,l}^{i,a}$ - share of population at country k in year l that will die in i years and is younger than a

$A_{k,l}^g$ - share of population younger than g at country k in year l

$X_{k,l}$ - GDP per capita (logarithm) at country k in year l

Generic model

$$h_{k,l} = \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (2)$$

or

$$h_{k,l} = \varphi h_{k,l-1} + \beta^i S_{i,a,k,l} + \alpha^a A_{g,k,l} + \theta_j X_{j,k,l} + \epsilon_{k,l} \quad (3)$$

where:

$h_{k,l}$ - the per capita health care expenditure in logarithm, at country k in year l

$S_{k,l}^{i,a}$ - share of population at country k in year l that will die in i years and is younger than a

$A_{k,l}^g$ - share of population younger than g at country k in year l

$X_{k,l}$ - GDP per capita (logarithm) at country k in year l

Model space

- estimation with the different combinations of
 - age-share: 5,10,...,95
 - time-to-death: 0,1,...,15
 - age threshold for time-to-death: 20,25,...,95
- various panel data estimators:
 - first difference OLS with robust standard errors
 - fixed effects with time dummies and robust standard errors
 - dynamic panel model Bond-Bover (system) estimator
- totally 12 960 models estimated, 270 for every time-to-death and every model



Model space


- estimation with the different combinations of
 - age-share: 5,10,...,95
 - time-to-death: 0,1,...,15
 - age threshold for time-to-death: 20,25,...,95
- various panel data estimators:
 - first difference OLS with robust standard errors
 - fixed effects with time dummies and robust standard errors
 - dynamic panel model Bond-Bover (system) estimator
- totally 12 960 models estimated, 270 for every time-to-death and every model




Model space

- estimation with the different combinations of
 - age-share: 5,10,...,95
 - time-to-death: 0,1,...,15
 - age threshold for time-to-death: 20,25,...,95
- various panel data estimators:
 - first difference OLS with robust standard errors
 - fixed effects with time dummies and robust standard errors
 - dynamic panel model Bond-Bover (system) estimator
- **totally 12 960 models estimated, 270 for every time-to-death and every model**


First difference




First difference




First difference




First difference




Fixed effects




Fixed effects




Fixed effects





Fixed effects






Blundell-Bond







Blundell-Bond



Blundell-Bond



Blundell-Bond



Blundell-Bond - significant and positive *beta*-s (time-to-death as endogenous variable)

- age-share: 90-95
- time-to-death threshold: 50, 55, 95
- time-to-death: 1-5, 14-15 (not 0)
- 0.2% of all models
- no significant models with negative *beta*



Blundell-Bond - significant and positive *beta*-s (time-to-death as endogenous variable)

- age-share: 90-95
- time-to-death threshold: 50, 55, 95
- time-to-death: 1-5, 14-15 (not 0)
- 0.2% of all models
- no significant models with negative *beta*



Blundell-Bond - significant and positive *beta*-s (time-to-death as endogenous variable)

- age-share: 90-95
- time-to-death threshold: 50, 55, 95
- **time-to-death: 1-5, 14-15 (not 0)**
- 0.2% of all models
- no significant models with negative *beta*



Blundell-Bond - significant and positive *beta*-s (time-to-death as endogenous variable)

- age-share: 90-95
- time-to-death threshold: 50, 55, 95
- time-to-death: 1-5, 14-15 (not 0)
- **0.2% of all models**
- no significant models with negative *beta*



Blundell-Bond - significant and positive *beta*-s (time-to-death as endogenous variable)

- age-share: 90-95
- time-to-death threshold: 50, 55, 95
- time-to-death: 1-5, 14-15 (not 0)
- 0.2% of all models
- no significant models with negative *beta*



Conclusions

- Age-share more robustly than time-to-death related to health care expenditure, however age-share remains insignificant in fixed effects model.
- Age-share surprisingly not robust, the exact decision of the age threshold 55, 60 or 75 might significantly influence the results.
- Time-to-death most often negative and insignificant.
- The reverse causality seems to be dominant - death rates are negatively related to health care expenditure, as higher health care expenditure reduces the mortality.
- The Blundell-Bond estimator is able to deal with the endogeneity of time-to-death.



Conclusions

- Age-share more robustly than time-to-death related to health care expenditure, however age-share remains insignificant in fixed effects model.
- Age-share surprisingly not robust, the exact decision of the age threshold 55, 60 or 75 might significantly influence the results.
- Time-to-death most often negative and insignificant.
- The reverse causality seems to be dominant - death rates are negatively related to health care expenditure, as higher health care expenditure reduces the mortality.
- The Blundell-Bond estimator is able to deal with the endogeneity of time-to-death.



Conclusions

- Age-share more robustly than time-to-death related to health care expenditure, however age-share remains insignificant in fixed effects model.
- Age-share surprisingly not robust, the exact decision of the age threshold 55, 60 or 75 might significantly influence the results.
- **Time-to-death most often negative and insignificant.**
- The reverse causality seems to be dominant - death rates are negatively related to health care expenditure, as higher health care expenditure reduces the mortality.
- The Blundell-Bond estimator is able to deal with the endogeneity of time-to-death.



Conclusions

- Age-share more robustly than time-to-death related to health care expenditure, however age-share remains insignificant in fixed effects model.
- Age-share surprisingly not robust, the exact decision of the age threshold 55, 60 or 75 might significantly influence the results.
- Time-to-death most often negative and insignificant.
- **The reverse causality seems to be dominant - death rates are negatively related to health care expenditure, as higher health care expenditure reduces the mortality.**
- The Blundell-Bond estimator is able to deal with the endogeneity of time-to-death.



Conclusions

- Age-share more robustly than time-to-death related to health care expenditure, however age-share remains insignificant in fixed effects model.
- Age-share surprisingly not robust, the exact decision of the age threshold 55, 60 or 75 might significantly influence the results.
- Time-to-death most often negative and insignificant.
- The reverse causality seems to be dominant - death rates are negatively related to health care expenditure, as higher health care expenditure reduces the mortality.
- **The Blundell-Bond estimator is able to deal with the endogeneity of time-to-death.**



Further questions?

maciej.lis@ibs.org.pl

